Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: Comparison with matched data from the general population and the effect of disease control

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 8, 2010, Pages 3648-3656

  Berg, Christian ^a   Petersenn, Stephan ^a   Lahner, Harald ^a   Herrmann, Burkhard L ^a   Buchfelder, Michael ^c   Droste, Michael ^d   Stalla, G̈unter K ^e   Strasburger, Christian J ^f   Roggenbuck, Ulla ^a   Lehmann, Nils ^a   Moebus, Susanne ^a,b   Jöckel, Karl Heinz ^a   Möhlenkamp, Stephan ^a   Erbel, Raimund ^b   Saller, Bernhard ^a,g   Mann, Klaus ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Charite Campus Mitte ^*

^e MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 77955392792     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2570     Document Type: Article

References (34)

1. Melmed S 1990 Acromegaly. N Engl J Med 322:966-977
2. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102-152
3. Orme SM, McNally RJ, Cartwright RA, Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730-2734
4. Sievers C, Dimopoulou C, Pfister H, Lieb R, Steffin B, Roemmler J, Schopohl J, Mueller M, Schneider HJ, Ising M, Wittchen HU, Stalla GK 2009 Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients. Clin Endocrinol (Oxf) 71:691-701
5. Courville C, Mason VR 1938 The heart in acromegaly. Arch Intern Med 61:704-713
6. Goldberg MB, Lisser H 1942 Acromegaly: a consideration of its course and treatment. Report of four cases with autopsies. J Clin Endocrinol 2:477-501
7. Hejtmancik MR, Bradfield Jr JY, Herrmann GR 1950 Acromegaly and heart: a clinical and pathologic study. Ann Intern Med 34:1445-1456
8. Lie JT 1980 Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 100:41-52
9. Otsuki M, Kasamaya S, Hiroyasu Y, Saito H, Sumitani S, Kouhara H, Saito Y, Ohnishi T, Arita N 2001 Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol (Oxf) 54:791-796
10. Greenland P, Gaziano JM 2003 Clinical practice. Selecting asymptomatic patients for coronary computed tomographic exercise testing. N Engl J Med 349:465-473
11. Cannavo S, Almoto B, Cavalli G, Squadrito S, Romanello G, Vigo MT, Fiumara F, Benvenga S, Trimarchi F 2006 Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab 91:3766-3772
12. Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, Cosci C, Sardella C, Volterrani D, Talini E, Pepe P, Falaschi F, Mariani G, Martino E 2007 Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 92:4271-4277
13. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ; German Pegvisomant Investigators 2007 Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75-82
14. Schmermund A, Möhlenkamp S, Stang A, Grönemeyer D, Seibel R, Hirche H, Mann K, Siffert W, Lauterbach K, Siegrist J, Jöckel KH, Erbel R 2002 Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcification and Lifestyle. Am Heart J 144:212-218
15. Möhlenkamp S, Moebus S, Schmermund A, Lehmann N, Hoffmann B, Neumann T, Stang A, Dragano N, Kerkhoff G, Naber C, Kälsch H, Beck EM, Bröcker-Preuss M, Kröger K, Budde T, Siegrist J, Mann K, Jöckel KH, Erbel R 2007 [Assessment of the natural history of coronary artery calcification and identification of its determinants. Rationale of the 2nd part of the Heinz Nixdorf Recall Study]. Herz 32:108-120 (German)
16. Barham AH, Goff Jr DC, Chen H, Balasubramanyam A, Rosenberger E, Bonds DE, Bertoni AG 2009 Appropriateness of cholesterol management in primary care by sex and level of cardiovascular risk. Prev Cardiol 12:95-101
17. Anderson C 1991 Risk assessment. End of an era. Nature 353:289
18. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol inplasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
19. Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso LF, Lombardi G, Pivonello R 2009 Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 94:528-537
20. Herrmann BL, Severing M, Schmermund A, Berg C, Budde T, Erbel R, Mann K 2009 Impact of disease duration on coronary calcification in patients with acromegaly. Exp Clin Endocrinol Diabetes 117:417-422
21. Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA 2006 Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 91:1239-1245
22. Rosén T, Bengtsson BA 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285-288
23. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM 2001 Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357:425-431
24. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS 2004 Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89: 1613-1617
25. Kauppinen-Mäkelin R, Sane T, Reunanen A, Välimäki MJ, Niskanen L, Markkanen H, Löyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E 2005 A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90:4081-4086
26. Saccà L, Cittadini A, Fazio S 1994 Growth hormone and the heart. Endocr Rev 15:555-573
27. Ciulla M, Arosio M, Barelli MV, Paliotti R, Porretti S, Valentini P, Tortora G, Buonamici V, Moraschi A, Capiello V, Magrini F 1999 Blood-pressure independent cardiac hypertrophy in acromegalic patients. J Hypertens 17:1965-1969
28. Clayton RN 2003 Cardiovascular function in acromegaly. Endocr Rev 24:272-277
29. Colao AM, Marzullo P, Di Somma C, Lombardi G 2001 Growth hormone and the heart. Clin Endocrinol (Oxf) 54:137-154
30. Colao A, Marzullo P, Lombardi G 2002 Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 146:303-309
31. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte op Reimer W, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Hellemans I, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen ML, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgözoglu L, Wiklund O, Zampelas A 2007 European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28:2375-2414
32. Hemann BA, Bimson WF, Taylor AJ 2007 The Framingham Risk Score: an appraisal of its benefits and limitations. Am Heart Hosp J 5:91-96
33. Gonzalez C, Rodilla E, Costa JA, Justicia J, Pascual JM 2006 [Cardiovascular risk by Framingham and SCORE in patients 40-65 years old]. Med Clin (Barc) 126:527-531 (Spanish)
34. de Visser CL, Bilo HJ, Thomsen TF, Groenier KH, Meyboom-de Jong B 2003 Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med 253:553-562